To our knowledge, the SOGUG-AUREA trial showed, for the first time, that the combination of atezolizumab with split doses of cisplatin and gemcitabine was effective and safe for patients with mUC ,” ...

This study “provides compelling evidence for incorporating oncology-trained pharmacists into hematology-oncology care teams,” researchers wrote.

US health officials have informed leading medical organizations that they will no longer be invited to participate in developing vaccination recommendations.